Current Report Filing (8-k)
June 15 2016 - 3:49PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): June 15, 2016 (June 14, 2016)
Valeant Pharmaceuticals International, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
British Columbia, Canada
|
|
001-14956
|
|
98-0448205
|
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S Employer
Identification No.)
|
2150 St Elzear Blvd, West
Laval, Quebec H7L 4A8
Canada
(Address of
principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code): (514) 744-6792
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
On June 14, 2016 the Company held its Annual
Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the shareholders of the Company voted on the following three proposals, each of which is described in detail in the Management Proxy Circular and Proxy Statement. The
results of each matter voted upon are as follows:
Proposal No. 1: Election of Directors.
The shareholders elected the following individuals
to the Company’s Board of Directors:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
For
|
|
|
Withheld
|
|
|
Broker Non-Votes
|
|
|
William A. Ackman
|
|
|
198,528,445
|
|
|
|
2,803,967
|
|
|
|
61,983,675
|
|
|
Dr. Frederic N. Eshelman
|
|
|
197,044,996
|
|
|
|
3,787,416
|
|
|
|
61,983,675
|
|
|
Stephen Fraidin
|
|
|
198,643,367
|
|
|
|
2,189,045
|
|
|
|
61,983,675
|
|
|
D. Robert Hale
|
|
|
196,991,641
|
|
|
|
3,840,771
|
|
|
|
61,983,675
|
|
|
Robert A. Ingram
|
|
|
185,459,606
|
|
|
|
15,372,806
|
|
|
|
61,983,675
|
|
|
Dr. Argeris (Jerry) N. Karabelas
|
|
|
198,470,956
|
|
|
|
2,361,456
|
|
|
|
61,983,675
|
|
|
Joseph C. Papa
|
|
|
195,388,625
|
|
|
|
5,443,787
|
|
|
|
61,983,675
|
|
|
Robert N. Power
|
|
|
187,463,060
|
|
|
|
13,369,352
|
|
|
|
61,983,675
|
|
|
Russel C. Robertson
|
|
|
198,700,104
|
|
|
|
2,132,308
|
|
|
|
61,983,675
|
|
|
Thomas W. Ross, Sr.
|
|
|
198,249,663
|
|
|
|
2,582,749
|
|
|
|
61,983,675
|
|
|
Amy B. Wechsler, M.D.
|
|
|
198,488,329
|
|
|
|
2,344,083
|
|
|
|
61,983,675
|
|
Proposal No. 2: Advisory Vote on Executive Compensation.
The shareholders approved, on a non-binding advisory
basis, the compensation of the Company’s Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Management Proxy Circular
and Proxy Statement.
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
|
124,660,750
|
|
75,280,731
|
|
890,931
|
|
61,983,675
|
Proposal No. 3: Appointment of the Independent Registered Public Accounting Firm.
The shareholders appointed
PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2017 Annual Meeting of Shareholders and authorized the Company’s Board of Directors to fix the auditors’ remuneration.
|
|
|
|
|
For
|
|
Withheld
|
|
259,520,100
|
|
3,295,987
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
VALEANT PHARMACEUTICALS
INTERNATIONAL, INC.
|
|
|
|
|
|
|
Date: June 15, 2016
|
|
|
|
By:
|
|
/s/ Robert R. Chai-Onn
|
|
|
|
|
|
|
|
Robert R. Chai-Onn
|
|
|
|
|
|
|
|
Executive Vice President, General Counsel
and Chief Legal Officer
|
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
